ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…
✓ Primary source cited
Last reviewed
Clinical Trials
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
Participants age 18 Years and older with Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-26
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-10-26
Cancer-type scope for this record is not yet recorded.
Participants age 18 Years and older with Metastatic Non-small Cell Lung Cancer With MTAP Deletion who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-23
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-10-23
Cancer-type scope for this record is not yet recorded.
Participants ages 18 Years to 123 Years with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed
2026-10-21
Regulatory status by jurisdiction
Country or region not specified
Status
Investigational
Last verified
2026-10-21
Cancer-type scope for this record is not yet recorded.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (with or without an anti-PD-(L)1 agent), randomized to tarlatamab or investigator's choice of chemotherapy, in the phase 3 DeLLphi-304 trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
Biomarker requirement
DLL3-expressing small cell lung cancer (target of the bispecific antibody; not a patient-selection biomarker test)
Adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy — a consolidation-therapy approval, not a first-line or newly-diagnosed LS-SCLC treatment broadly, and specifically the durvalumab-monotherapy regimen, not the durvalumab-plus-tremelimumab arm also tested in the same trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy, as consolidation therapy with durvalumab monotherapy.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.